Cardiotoxicity and oncological treatments.

BACKGROUND Cardiotoxic and other side effects limit the usefulness of treatments for cancer. METHOD This article is based on pertinent articles that were retrieved by a selective search in PubMed and other databases, and on the guidelines of the European Society of Cardiology, the Association of Scientific Medical Societies in Germany, and the European Society of Medical Oncology. RESULTS Prospective studies have shown that some treatments for cancer are cardiotoxic. The heart damage that they cause can manifest itself as arrhythmia, arterial hypertension, thromboembolism, angina pectoris, myocardial infarction, or heart failure. It has been observed that potentially lethal complications can arise as late as 40 years after treatment of the original cancer. The anthracycline drug doxorubicin, given in a dose of 500 mg/m2 of body surface area, has been found to cause cardiac complications in 4-36% of the patients treated with it. Trastuzumab and epirubicin cause dose-limiting cardiac events in 1.7-5% of patients, depending on the dosage. Paclitaxel causes bradycardia, intracardiac conduction block, or arrhythmia in 0.5% of patients. 18% of patients treated with sunitimib or sorafenib have clinical manifestations relating to the heart (angina pectoris, dyspnea). 5-fluorouracil can cause angina pectoris at the beginning of treatment and rarely causes myocardial infarction. Cardiac radiation therapy, a form of treatment practiced in earlier decades, can cause cardiac complications 20 years after the event. The opportunity to prevent cardiac complications of anthracycline drugs with dexrazoxane is decidedly limited, but initial studies have shown that treatment with beta-blockers and ACE inhibitors lessens the likelihood of cardiotoxic side effects. When cardiac complications arise, the generally applicable rules for the treatment of each type of cardiac problem should be followed. The oncological treatment protocol should be adjusted or switched to one that is less damaging to the heart. CONCLUSION Treating physicians need to be thoroughly acquainted with the cardiotoxic effects of anti-cancer drugs so that they can diagnose them early on and avoid jeopardizing the overall success of treatment.

[1]  A. Bedewy,et al.  XPD gene polymorphisms and the effects of induction chemotherapy in cytogenetically normal de novo acute myeloid leukemia patients , 2014, Hematology.

[2]  J. Esteve,et al.  Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. , 2013, Journal of the American College of Cardiology.

[3]  P. Mazzanti,et al.  State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. , 2013, Critical reviews in oncology/hematology.

[4]  B. Khandheria,et al.  Cardioncology: state of the heart. , 2013, International journal of cardiology.

[5]  G. Armstrong,et al.  Clinical ascertainment of health outcomes among adults treated for childhood cancer. , 2013, JAMA.

[6]  J. Esteve,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.

[7]  P. Hall,et al.  Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.

[8]  C. Geyer,et al.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[10]  C. Koning,et al.  High risk of symptomatic cardiac events in childhood cancer survivors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Moja,et al.  Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.

[12]  G. Ertl,et al.  [The German National Disease Management Guideline "Chronic Heart Failure"]. , 2012, Deutsche medizinische Wochenschrift.

[13]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[14]  H. Caron,et al.  The use of liposomal anthracycline analogues for childhood malignancies: A systematic review. , 2011, European journal of cancer.

[15]  D. Cunningham,et al.  Cardiotoxicity in patients treated with bevacizumab is potentially reversible. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Mantovani,et al.  Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. , 2011, Experimental and therapeutic medicine.

[17]  M. Beer,et al.  Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. , 2011, International Journal of Radiation Oncology, Biology, Physics.

[18]  R. Pötter,et al.  Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow‐up project of the German–Austrian DAL‐HD studies , 2010, Pediatric blood & cancer.

[19]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[20]  F. Roila,et al.  Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[23]  R. Kreienberg,et al.  First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[25]  E. D. de Vries,et al.  Cardiovascular toxicity caused by cancer treatment: strategies for early detection. , 2009, The Lancet. Oncology.

[26]  R. Hoffmann,et al.  Manual zur Indikation und Durchführung der Echokardiographie , 2009 .

[27]  F. Holmes,et al.  Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Bokemeyer,et al.  Kardiotoxizitäten bei Chemo- und Radiotherapie , 2009, Der Onkologe.

[29]  M. Kalmanti,et al.  Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity , 2008, Pediatric blood & cancer.

[30]  L. Wojnowski,et al.  [Chemotherapeutics-induced heart failure]. , 2007, Medizinische Klinik.

[31]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  C. Angermann,et al.  3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures , 2006, Radiation oncology.

[33]  S. Bielack,et al.  Prospective longitudinal evaluation of doxorubicin‐induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS) , 2006, Pediatric blood & cancer.

[34]  J. Goodwin,et al.  Cardiac morbidity of adjuvant radiotherapy for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[36]  James S Goodwin,et al.  Risk of cardiac death after adjuvant radiotherapy for breast cancer. , 2005, Journal of the National Cancer Institute.

[37]  S. Lipsitz,et al.  Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Hall Essential biochemistry and physiology of (NT‐pro)BNP , 2004, European journal of heart failure.

[39]  Giovanni Martinelli,et al.  Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. , 2003, Clinical chemistry.

[40]  M. Sigmund,et al.  Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[42]  L. Burke,et al.  Symptomatic Cardiotoxicity Associated with 5‐Fluorouracil , 1997, Pharmacotherapy.

[43]  J. Krischer,et al.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Hortobagyi,et al.  Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. Jungius,et al.  [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. , 1996, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[46]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  F. Bu'Lock,et al.  Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. , 1995, British heart journal.

[48]  S. Sallan,et al.  Cardiovascular abnormalities in long-term survivors of childhood malignancy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Kloner,et al.  5‐Fluorouracil Cardiotoxicity: Left Ventricular Dysfunction and Effect of Coronary Vasodilators , 1987, The American journal of the medical sciences.

[50]  A. Burger,et al.  5-Fluorouracil-induced coronary vasospasm. , 1987, American heart journal.

[51]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[52]  D. V. Von Hoff,et al.  Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. , 1977, The American journal of medicine.

[53]  M. Zibelman,et al.  Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer , 2013 .

[54]  M. Dowsett,et al.  years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial , 2013 .

[55]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[56]  P. Russo Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma , 2009 .

[57]  Risk of proteinuria, hypertension with bevacizumab , 2007 .

[58]  H. Dickinson,et al.  Cardioprotective interventions for cancer patients receiving anthracyclines. , 2005, The Cochrane database of systematic reviews.

[59]  P. Vici,et al.  The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review , 2003, Journal of Cancer Research and Clinical Oncology.

[60]  Steven E Lipshultz,et al.  Radiation-associated cardiovascular disease. , 2003, Critical reviews in oncology/hematology.

[61]  G Noël,et al.  [Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[62]  P. Kaufmann,et al.  Cardiac risk after mediastinal irradiation for Hodgkin's disease. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[63]  M. Christian,et al.  A reassessment of cardiac toxicity associated with Taxol. , 1993, Journal of the National Cancer Institute. Monographs.